Alembic Pharma rating – Hold: India sales bright spot of Q3FY21
Execution key for India and US sales; FY21-22e EPS up 3%; valuations factor in prospects; ‘Hold’ retained
Execution key for India and US sales; FY21-22e EPS up 3%; valuations factor in prospects; ‘Hold’ retained
55/36/29% rise in EPS for FY21-23e; TP up to Rs 1,491; upgraded to ‘Neutral’ rating
Biden to reinstate Covid travel bans: White House official
Milan, Inter look to bounce back in last-eight derby cup clash
Greece, Turkey face first crisis talk since 2016
Australia approves Pfizer vaccine for rollout in February
WASHINGTON -- Officials in President Joe Biden's administration tried to head off Republican concerns that his $1.9 trillion pandemic relief proposal was too expensive on a Sunday call with Republican and Democratic lawmakers, some of whom pushed for a smaller plan targeting vaccine distribution. Read
HANOI -- Copper prices fell on Monday on demand worries due to rising coronavirus cases in top consumer China and ahead of seasonally slow consumption during the Lunar New Year holiday. Read More
SINGAPORE -- Oil prices slipped for a second straight session on Monday as renewed COVID-19 lockdowns raised fresh concerns about global fuel demand. Read More